ACC-1898

ACC-1898 is an investigational, orally administered, small-molecule multi-targeted receptor tyrosine kinase inhibitor being developed for the treatment of advanced solid tumors, including melanoma, renal cell carcinoma, and radioactive iodine–refractory differentiated thyroid cancer. It potently inhibits several oncogenic receptor tyrosine kinases such as vascular endothelial growth factor receptor 2 (VEGFR2), mesenchymal-epithelial transition factor (c-MET), AXL receptor tyrosine kinase, platelet-derived growth factor receptor alpha (PDGFRA), rearranged during transfection (RET), and KIT, thereby blocking signaling pathways that drive tumor proliferation, angiogenesis, survival, and metastasis.[1][3] ACC-1898 (also known as ST-1898) is being evaluated in first-in-human Phase 1 studies in adults with advanced or metastatic solid tumors after failure of standard therapies, with AccSalus Biosciences sponsoring ex-China development and Beijing Saite Mingqiang Pharmaceutical Technology leading development as ST-1898 in China.[1][3]

Other names

ST1898ST-1898ST 1898